

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Dox 1450 Alexandria, Virginia 22313-1450

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATT	Y. DOCKET NO.
10/502,085	Zi-Hua Jiang	JIANG4A / INTERNATIONAL APPLICATION NO. PCT/CA03/00135	
	_		
)1444	Г	I.A. FILING DATE	PRIORITY DATE
ROWDY AND NEIMARK, P.L.L.C.	_	02/04/2003	02/04/2002

00 BF 624 NINTH STREET, NW SUITE 300 **WASHINGTON, DC 20001-5303** 

**CONFIRMATION NO. 3733 371 FORMALITIES LETTER** \*OC00000016945978\*

\*OC00000016945978\*

Date Mailed: 09/07/2005

### NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Indication of Small Entity Status
- Priority Document
- Copy of the International Application filed on 07/22/2004
- Copy of the International Search Report filed on 07/22/2004
- Preliminary Amendments filed on 04/12/2005
- Biochemical Sequence Diskette filed on 06/08/2005
- Oath or Declaration filed on 04/12/2005
- Biochemical Sequence Listing filed on 06/08/2005
- Request for Immediate Examination filed on 07/22/2004
- U.S. Basic National Fees filed on 07/22/2004
- Priority Documents filed on 07/22/2004
- Power of Attorney filed on 07/22/2004

LESAUNDE = 070C 2005. NON EOT

Applicant's response filed 06/08/2005 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 12/17/2004 have not been completed.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

 The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8. 2000) and 1238 OG 145 (September 19, 2000).

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

For questions regarding compliance to 37 CFR 1:821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

SHAKEEL AHMED

Telephone: (703) 308-9140 EXT 208

### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/502,085	PCT/CA03/00135	ЛАNG4A

FORM PCT/DO/EO/916 (371 Formalities Notice)

## STIC Biotechnology Systems Branch

# RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	10/502/085A
Source:	PCT
Date Processed by STIC:	7-7-05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.2.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

## Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 10502, 0851
ATTN: NEW RULES CASES	: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
IWrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Amino Numbering	The numbering under each 5 <sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
•	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing.  Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
IOInvalid 213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
Use of <220>	Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
"bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
3 Misuse of n/Xaa	"n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid
•	AMC - Biotechnology Systems Branch - 09/09/2003



PCT

RAW SEQUENCE LISTING DATE: 07/07/2005
PATENT APPLICATION: US/10/502,085A TIME: 13:46:34

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\07072005\J502085A.raw

```
3 <110> APPLICANT: BIOMIRA INC. et al.
      5 <120> TITLE OF INVENTION: IMMUNOSTIMULATORY, COVALENTLY LIPIDATED OIGONUCLEOTIDES
      7 <130> FILE REFERENCE: JIANG=4A PCT
C--> 9 <140> CURRENT APPLICATION NUMBER: US/10/502,085A
C--> 10 <141> CURRENT FILING DATE: 2004-07-22
     12 <150> PRIOR APPLICATION NUMBER: 60/353,195
                                                                     Does Not Comply
     13 <151> PRIOR FILING DATE: 2002-02-04
                                                                     Corrected Diskette Needed
     15 <160> NUMBER OF SEQ ID NOS: 12
     17 <170> SOFTWARE: PatentIn version 3.3
     19 <210> SEO ID NO: 1
     20 <211> LENGTH: 10
     21 <212> TYPE: DNA
     22 <213> ORGANISM: (Artificial Sequence
     24 <220> FEATURE:
     25 <223> OTHER INFORMATION: 128H described in Cheng et al. USP 5,646,126
     27 <400> SEQUENCE: 1
     28 cacacgtgtg
     31 <210> SEQ ID NO: 2
     32 <211> LENGTH: 25
     33 <212> TYPE: PRT
     34 <213> ORGANISM: Artificial Sequence
     36 <220> FEATURE:
     37 <223> OTHER INFORMATION: Synthesized peptide shown in Fig. 17 BP1-148
     39 <400> SEQUENCE: 2
     41 Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg
     45 Pro Ala Pro Gly Ser Thr Ala Pro Pro
                    20 -
     49 <210> SEQ ID NO: 3
     50 <211> LENGTH: 20
    51 <212> TYPE: DNA
    52 <213> ORGANISM: Artificial Sequence
    54 <220> FEATURE:
    55 <223> OTHER INFORMATION: Synthesizable activating sequence, shown in Fig. 1
    57 <400> SEQUENCE: 3
    58 ggtgcatcga tgcaggggg
                                                                               20
    61 <210> SEQ ID NO: 4
    62 <211> LENGTH: 10
    63 <212> TYPE: PRT
    64 <213> ORGANISM: Leishmani major
    66 <400> SEQUENCE: 4
    68 Glu Ala Glu Glu Ala Ala Arg Leu Gln Ala
```

69 1

RAW SEQUENCE LISTING DATE: 07/07/2005
PATENT APPLICATION: US/10/502,085A TIME: 13:46:34

Input Set : A:\sequence listing.txt
Output Set: N:\CRF4\07072005\J502085A.raw

72 <210> SEQ ID NO: 5 73 <211> LENGTH: 25 74 <212> TYPE: PRT 75 <213> ORGANISM: Artificial Sequence 77 <220> FEATURE: 78 <223> OTHER INFORMATION: MUC1 repeat consensus sequence 80 <400> SEQUENCE: 5 82 Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala Gln Thr Ala His Gly Val . 10 86 Thr Ser Ala Pro Asp Glu Thr Ser Arg 87 20 90 <210> SEQ ID NO: 6 91 <211> LENGTH: 12 92 <212> TYPE: PRT 93 <213> ORGANISM: Artificial Sequence 95 <220> FEATURE: 96 <223> OTHER INFORMATION: MUC1 fragment 98 <400> SEQUENCE: 6 100 Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr 104 <210> SEQ ID NO: 7 105 <211> LENGTH: 9 106 <212> TYPE: PRT 107 <213> ORGANISM: Artificial Sequence 109 <220> FEATURE: 110 <223> OTHER INFORMATION: MUC1 fragment 112 <400> SEQUENCE: 7 114 Thr Leu Ala Pro Ala Thr Glu Pro Ala 115 1 118 <210> SEQ ID NO: 8 119 <211> LENGTH: 9 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 124 <223> OTHER INFORMATION: MUC1 fragment 126 <400> SEQUENCE: 8 128 Ala Leu Gly Ser Thr Ala Pro Pro Val 129 1 132 <210> SEQ ID NO: 9 133 <211> LENGTH: 9 134 <212> TYPE: PRT 135 <213> ORGANISM: Artificial Sequence 137 <220> FEATURE: 138 <223> OTHER INFORMATION: MUC1 fragment 140 <400> SEQUENCE: 9 142 Phe Leu Ser Phe His Ile Ser Asn Leu 143 1 146 <210> SEQ ID NO: 10 147 <211> LENGTH: 20

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/502,085A

DATE: 07/07/2005 TIME: 13:46:34

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\07072005\J502085A.raw

- 148 <212> TYPE: PRT
- 149 <213> ORGANISM: Artificial Sequence
- 151 <220> FEATURE:
- 152 <223> OTHER INFORMATION: MUC1 repeat
- 154 <400> SEQUENCE: 10
- 156 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala
- 157 1 5 10
- 160 Pro Pro Ala His
- 161 20
- 164 <210> SEQ ID NO: 11
- 165 <211> LENGTH: 28
- 166 <212> TYPE: PRT
- 167 <213> ORGANISM: Artificial Sequence
- 169 <220> FEATURE:
- 170 <223> OTHER INFORMATION: Synthesized peptide shown in Fig. 17 as intermediate
- 173 <220> FEATURE:
- 174 <221> NAME/KEY: misc\_feature
- 175 <222> LOCATION: (27)..(27)
- 176 <223> OTHER INFORMATION: Lys is modified by a palmitoyl group
- 178 <400> SEQUENCE: 11
- 180 Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Pro Asp Thr
- 181 1 5 10
- 184 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Lys Gly
- 185 20 2
- 188 <210> SEQ ID NO: 12
- 189 <211> LENGTH: 12
- 190 <212> TYPE: PRT
- 191 <213> ORGANISM: Plasmodium falciparum
- 193 <400> SEQUENCE: 12
- 195 Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro
- 196 1

5

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/502,085A

DATE: 07/07/2005

TIME: 13:46:35

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\07072005\J502085A.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application Number L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date